About Alder Biopharmaceuticals (NASDAQ:ALDR)
Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.
Industry, Sector and Symbol
Trailing P/E Ratio-2.18689366687155
Forward P/E Ratio-2.67
Sales & Book Value
Annual Sales$1.62 million
Price / Sales475.37
Price / CashN/A
Book Value$4.12 per share
Price / Book2.75
Return on Equity-103.76%
Return on Assets-93.09%
Alder Biopharmaceuticals (NASDAQ:ALDR) Frequently Asked Questions
What is Alder Biopharmaceuticals' stock symbol?
Alder Biopharmaceuticals trades on the NASDAQ under the ticker symbol "ALDR."
How were Alder Biopharmaceuticals' earnings last quarter?
Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings results on Monday, February, 26th. The biopharmaceutical company reported ($0.80) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.03) by $0.23. The biopharmaceutical company had revenue of $0.94 million for the quarter. During the same quarter in the prior year, the business earned ($0.97) earnings per share. View Alder Biopharmaceuticals' Earnings History.
Where is Alder Biopharmaceuticals' stock going? Where will Alder Biopharmaceuticals' stock price be in 2018?
12 equities research analysts have issued twelve-month price targets for Alder Biopharmaceuticals' shares. Their forecasts range from $11.00 to $51.00. On average, they anticipate Alder Biopharmaceuticals' share price to reach $30.67 in the next twelve months. View Analyst Ratings for Alder Biopharmaceuticals.
What are Wall Street analysts saying about Alder Biopharmaceuticals stock?
Here are some recent quotes from research analysts about Alder Biopharmaceuticals stock:
- 1. According to Zacks Investment Research, "Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and psoriatic arthritis. Alder Biopharmaceuticals Inc. is headquartered in Bothell, Washington. " (3/1/2018)
- 2. Mizuho analysts commented, "We received an email from Alder yesterday on its recap of the 18th Congress of the International Headache Society (IHC) meeting as it relates to eptinezumab. What we found as incremental data points are Alder’s interviews with practicing physicians on the advantages of eptinezumab. We believe the IV formulation for eptinezumab is a positive differentiation from other CGRP products in late stage development because of its reimbursement and potentially better compliance." (9/15/2017)
- 3. Needham & Company LLC analysts commented, "Results from the ongoing pivotal Phase 3 PROMISE-1 trial in patients with frequent episodic migraines (FEM) are expected this month. In the context of positive Phase 3 FEM results from all competitor CGRP antibody programs (AMGN, LLY, TEVA), we think PROMISE-1’s primary endpoint will generally be in-line with the competition. However, we expect differentiation with key secondary endpoints (≥75% reduction in migraine days over weeks 1-12 and weeks 1-4), which we think will be important for commercial success. We maintain our view that there is room for multiple players in the migraine prophylaxis market, and we believe Alder shares remain underappreciated even in a scenario where PROMISE-1 data are positive but undifferentiated. Alder’s current EV (~$550M) reflects treatment of just ~63k patients with eptinezumab in 2027 in our model, or <1% of our estimated 7.1M prevention therapy candidates."" (6/9/2017)
- 4. Aegis analysts commented, "We conducted an in-depth analysis of four late-stage monoclonal antibodies in development for migraine prevention – See table 1." (4/10/2017)
Who are some of Alder Biopharmaceuticals' key competitors?
Some companies that are related to Alder Biopharmaceuticals include Motif Bio (MTFB), Myokardia (MYOK), Clinigen Group (CLIGF), Editas Medicine (EDIT), Aimmune Therapeutics (AIMT), Cambrex (CBM), Heron Therapeutics (HRTX), Madrigal Pharmaceuticals (MDGL), Enanta Pharmaceuticals (ENTA), ImmunoGen (IMGN), Innoviva (INVA), Immuron Limited - American Depositary Shares (IMRN), Atara Biotherapeutics (ATRA), Intercept Pharmaceuticals (ICPT), Arena Pharmaceuticals (ARNA), Repligen (RGEN), Radius Health (RDUS) and Xencor (XNCR).
Who are Alder Biopharmaceuticals' key executives?
Alder Biopharmaceuticals' management team includes the folowing people:
- Stephen M. Dow, Independent Chairman of the Board (Age 61)
- Randall C. Schatzman Ph.D., President, Chief Executive Officer, Director (Age 62)
- Larry K. Benedict, Executive Vice President, Principal Accounting Officer (Age 56)
- Elisabeth A. Sandoval, Chief Commercial Officer and Executive Vice President of Corporate Strategy (Age 55)
- James B. Bucher J.D., Senior Vice President, General Counsel (Age 51)
- Randal A. Hassler, Senior Vice President - Pharmaceutical Operations (Age 59)
- John A. Latham Ph.D., Chief Scientific Officer (Age 57)
- Mark James Litton Ph.D., Chief Business Officer, Treasurer and Secretary (Age 49)
- Jeffrey T.L. Smith M.D., Managing Director of Alder BioPharmaceuticals Limited (Age 57)
- Paul Rutherford Carter, Independent Director (Age 56)
Has Alder Biopharmaceuticals been receiving favorable news coverage?
Media headlines about ALDR stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alder Biopharmaceuticals earned a media sentiment score of 0.19 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 45.87 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
Who are Alder Biopharmaceuticals' major shareholders?
Alder Biopharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (9.59%), BlackRock Inc. (7.34%), Palo Alto Investors LLC (2.71%), Emerald Advisers Inc. PA (2.55%), Goldman Sachs Group Inc. (2.45%) and Pinnacle Associates Ltd. (1.99%). Company insiders that own Alder Biopharmaceuticals stock include Jeffrey T L Smith, John A Latham, Mark James Litton, Randall C Schatzman and Stephen M Dow. View Institutional Ownership Trends for Alder Biopharmaceuticals.
Which major investors are selling Alder Biopharmaceuticals stock?
ALDR stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, BlackRock Inc., Metropolitan Life Insurance Co. NY, Candriam Luxembourg S.C.A., Baird Financial Group Inc., Rhumbline Advisers and Sequoia Financial Advisors LLC. Company insiders that have sold Alder Biopharmaceuticals company stock in the last year include Jeffrey T L Smith and Mark James Litton. View Insider Buying and Selling for Alder Biopharmaceuticals.
Which major investors are buying Alder Biopharmaceuticals stock?
ALDR stock was acquired by a variety of institutional investors in the last quarter, including Palo Alto Investors LLC, Carillon Tower Advisers Inc., Brown Advisory Inc., TIAA CREF Investment Management LLC, Millennium Management LLC, Rock Springs Capital Management LP, Ascend Capital LLC and Emerald Advisers Inc. PA. View Insider Buying and Selling for Alder Biopharmaceuticals.
How do I buy shares of Alder Biopharmaceuticals?
Shares of ALDR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Alder Biopharmaceuticals' stock price today?
One share of ALDR stock can currently be purchased for approximately $11.33.
How big of a company is Alder Biopharmaceuticals?
Alder Biopharmaceuticals has a market capitalization of $922.69 million and generates $1.62 million in revenue each year. The biopharmaceutical company earns $-288,870,000.00 in net income (profit) each year or ($5.19) on an earnings per share basis. Alder Biopharmaceuticals employs 193 workers across the globe.
How can I contact Alder Biopharmaceuticals?
Alder Biopharmaceuticals' mailing address is 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA, 98011. The biopharmaceutical company can be reached via phone at 425-205-2900 or via email at [email protected]
MarketBeat Community Rating for Alder Biopharmaceuticals (ALDR)MarketBeat's community ratings are surveys of what our community members think about Alder Biopharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Alder Biopharmaceuticals (NASDAQ:ALDR) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.92||2.92||2.92||2.91|
|Ratings Breakdown: ||0 Sell Rating(s)|
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$30.67||$30.42||$30.58||$33.82|
|Price Target Upside: ||170.19% upside||114.20% upside||152.23% upside||241.60% upside|
Alder Biopharmaceuticals (NASDAQ:ALDR) Consensus Price Target History
Alder Biopharmaceuticals (NASDAQ:ALDR) Analyst Ratings History
(Data available from 3/22/2016 forward)
Alder Biopharmaceuticals (NASDAQ:ALDR) Earnings History and Estimates Chart
Alder Biopharmaceuticals (NASDAQ ALDR) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/26/2018||Q4 2017||($1.03)||($0.80)||$0.94 million||View||Listen|
|8/8/2017||Q2 2017||($1.67)||($1.48)||$0.68 million||View||Listen|
|7/26/2016||Q2||($0.75)||($0.79)||$1.14 million||$0.11 million||View||Listen|
|3/4/2015||Q414||($0.18)||($0.22)||$5.70 million||$6.40 million||View||N/A|
|11/3/2014||Q314||$0.05||$0.88||$14.84 million||$38.75 million||View||N/A|
|8/5/2014||Q2||($0.22)||($0.40)||$5.00 million||$4.70 million||View||N/A|
|6/20/2014||Q1||($0.22)||($5.38)||$4.60 million||$4.80 million||View||N/A|
Alder Biopharmaceuticals (NASDAQ:ALDR) Earnings Estimates
2018 EPS Consensus Estimate: ($4.28)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Alder Biopharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by MarketBeat.com
Alder Biopharmaceuticals (NASDAQ ALDR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 99.14%
Alder Biopharmaceuticals (NASDAQ ALDR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|11/13/2017||Mark James Litton||Insider||Sell||16,519||$10.80||$178,405.20||116,451|| |
|10/16/2017||Mark James Litton||Insider||Sell||16,520||$12.33||$203,691.60||116,452|| |
|7/18/2017||Stephen M Dow||Director||Buy||25,000||$10.00||$250,000.00|| |
|6/20/2017||Jeffrey T L Smith||VP||Sell||585||$20.00||$11,700.00||1,416|| |
|1/18/2017||Mark James Litton||Insider||Sell||1,498||$23.10||$34,603.80||101,430|| |
|1/9/2017||Mark James Litton||Insider||Sell||9,516||$23.01||$218,963.16|| |
|12/1/2016||Jeffrey T. L. Smith||VP||Sell||3,000||$22.78||$68,340.00|| |
|12/1/2016||John A. Latham||Insider||Sell||3,636||$22.78||$82,828.08|| |
|11/7/2016||Randall C Schatzman||CEO||Sell||10,000||$25.16||$251,600.00||124,768|| |
|10/17/2016||Mark James Litton||Insider||Sell||6,000||$27.50||$165,000.00||99,567|| |
|10/3/2016||Jeffrey T L Smith||VP||Sell||3,000||$31.14||$93,420.00||3,000|| |
|10/3/2016||John A Latham||Insider||Sell||10,000||$31.32||$313,200.00||252,200|| |
|10/3/2016||Randall C Schatzman||CEO||Sell||8,181||$31.15||$254,838.15||122,949|| |
|9/1/2016||Jeffrey T L Smith||VP||Sell||3,000||$32.49||$97,470.00||3,000|| |
|9/1/2016||Randall C Schatzman||Insider||Sell||10,000||$32.48||$324,800.00||124,768|| |
|8/15/2016||Jeffrey T L Smith||VP||Sell||3,000||$31.17||$93,510.00||3,000|| |
|8/1/2016||John A Latham||Insider||Sell||10,000||$31.19||$311,900.00||252,200|| |
|7/27/2016||John A Latham||Insider||Sell||10,000||$30.14||$301,400.00||243,013|| |
|7/25/2016||Randall C Schatzman||Insider||Sell||10,000||$28.08||$280,800.00||124,768|| |
|6/13/2016||Mark James Litton||Insider||Sell||6,000||$28.94||$173,640.00||74,567|| |
|6/3/2016||Jeffrey T L Smith||VP||Sell||16,090||$30.20||$485,918.00||16,090|| |
|6/1/2016||John A Latham||Insider||Sell||10,000||$30.02||$300,200.00||252,200|| |
|5/31/2016||Mark James Litton||Insider||Sell||25,000||$30.05||$751,250.00||79,847|| |
|5/27/2016||John A Latham||Insider||Sell||6,401||$30.05||$192,350.05||248,601|| |
|5/24/2016||Randall C Schatzman||CEO||Sell||10,000||$28.02||$280,200.00||115,933|| |
|4/18/2016||Randall C Schatzman||CEO||Sell||30,000||$28.07||$842,100.00||124,409|| |
|1/4/2016||Mark James Litton||insider||Sell||25,000||$31.40||$785,000.00||73,718|| |
|1/4/2016||Randall C. Schatzman||CEO||Sell||10,000||$31.47||$314,700.00||111,579|| |
|12/1/2015||Jeffrey T. L. Smith||VP||Sell||4,272||$37.24||$159,089.28|| |
|12/1/2015||John A. Latham||insider||Sell||4,550||$37.24||$169,442.00||241,726|| |
|12/1/2015||Randall C. Schatzman||CEO||Sell||10,000||$37.24||$372,400.00||111,579|| |
|11/30/2015||Stephen M Dow||Director||Sell||88||$37.11||$3,265.68|| |
|11/2/2015||Jeffrey T. L. Smith||VP||Sell||3,900||$33.67||$131,313.00|| |
|11/2/2015||John A. Latham||insider||Sell||4,545||$33.69||$153,121.05||241,265|| |
|11/2/2015||Randall C. Schatzman||CEO||Sell||10,000||$33.71||$337,100.00||109,921|| |
|10/1/2015||Jeffrey T. L. Smith||VP||Sell||3,900||$32.25||$125,775.00|| |
|10/1/2015||John A. Latham||insider||Sell||4,545||$32.26||$146,621.70||241,265|| |
|9/1/2015||Jeffrey T. L. Smith||VP||Sell||3,900||$38.50||$150,150.00|| |
|9/1/2015||John A. Latham||insider||Sell||4,545||$38.52||$175,073.40||209,447|| |
|8/31/2015||Stephen M Dow||Director||Sell||16,218||$38.75||$628,447.50|| |
|6/12/2015||Larry Benedict||VP||Sell||25,454||$47.46||$1,208,046.84|| |
|6/4/2015||John A Latham||Insider||Sell||25,000||$44.18||$1,104,500.00|| |
|6/1/2015||Jeffrey T L Smith||VP||Sell||3,900||$41.53||$161,967.00|| |
|6/1/2015||John A Latham||Insider||Sell||4,545||$41.53||$188,753.85|| |
|5/22/2015||Jeffrey T L Smith||VP||Sell||61,818||$38.86||$2,402,247.48|| |
|5/21/2015||Stephen M Dow||Director||Sell||20,000||$65.69||$1,313,800.00|| |
|5/20/2015||Stephen M Dow||Director||Sell||8,462||$40.39||$341,780.18|| |
|5/18/2015||Clay B Siegall||Director||Sell||38,181||$37.62||$1,436,369.22|| |
|4/1/2015||Jeffrey T L Smith||VP||Sell||3,900||$27.43||$106,977.00|| |
|4/1/2015||John A Latham||Insider||Sell||19,045||$29.54||$562,589.30|| |
|3/30/2015||John A Latham||Insider||Sell||14,500||$30.20||$437,900.00|| |
|1/27/2015||Jeffrey T L Smith||VP||Sell||3,900||$28.01||$109,239.00|| |
|1/27/2015||John A Latham||Insider||Sell||15,045||$28.33||$426,224.85|| |
|1/27/2015||Randall C Schatzman||CEO||Sell||100,000||$28.42||$2,842,000.00|| |
|1/26/2015||Jeffrey T L Smith||VP||Sell||2,700||$27.89||$75,303.00|| |
|1/26/2015||Mark James Litton||Insider||Sell||5,200||$28.03||$145,756.00|| |
|1/26/2015||Randall C Schatzman||CEO||Sell||36,422||$27.93||$1,017,266.46|| |
|11/24/2014||Jeffrey T L Smith||VP||Sell||29,090||$16.08||$467,767.20|| |
|5/13/2014||A/S Novo||Insider||Buy||550,000||$10.00||$5,500,000.00|| |
|5/13/2014||Alan Bruce Montgomery||Director||Buy||3,000||$10.00||$30,000.00|| |
|5/13/2014||West 8 Limited Partne Ventures||Major Shareholder||Buy||250,000||$10.00||$2,500,000.00|| |
Alder Biopharmaceuticals (NASDAQ ALDR) News Headlines
Alder Biopharmaceuticals (NASDAQ:ALDR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Alder Biopharmaceuticals (NASDAQ:ALDR) Income Statement, Balance Sheet and Cash Flow Statement
Alder Biopharmaceuticals (NASDAQ ALDR) Stock Chart for Thursday, March, 22, 2018